Invasive fusariosis in patients with hematologic malignancies at a cancer center: 1998-2009

Journal of Infection

Volumn 60, Issue 5, 2010, Pages 331-337

  Campo, Marcela ^a   Lewis, Russell E ^a,b   Kontoyiannis, Dimitrios P ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF HOUSTON   (United States)

Author keywords

Fusarium; Leukemia

Indexed keywords

AMPHOTERICIN B; ECHINOCANDIN; POSACONAZOLE; TRIAZOLE; VORICONAZOLE;

ADOLESCENT; ADULT; AGED; ARTICLE; ATTRIBUTABLE RISK; BLOOD CULTURE; CANCER CENTER; CANCER DIAGNOSIS; CAUSE OF DEATH; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DEMOGRAPHY; DISEASE ASSOCIATION; FEMALE; FUNGEMIA; FUSARIOSIS; FUSARIUM; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INTENSIVE CARE UNIT; LUNG INFECTION; MALE; MIXED INFECTION; MORTALITY; NEUTROPENIA; PATIENT IDENTIFICATION; PREDICTION; PROGNOSIS; RISK FACTOR; SCHOOL CHILD; SINUSITIS; SKIN INFECTION; SURVIVAL RATE; TREATMENT DURATION; TREATMENT OUTCOME; UNITED STATES;

ADOLESCENT; ADULT; AGED; ANTIFUNGAL AGENTS; CHILD; DRUG THERAPY, COMBINATION; FEMALE; FUSARIUM; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOCOMPROMISED HOST; MALE; MIDDLE AGED; MYCOSES; PREVALENCE; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; YOUNG ADULT;

EID: 77952544533     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jinf.2010.01.010     Document Type: Article

References (22)

1. Boutati E.I., Anaissie E.J. Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years' experience at a cancer center and implications for management. Blood 1997, 90:999-1008.
2. Kontoyiannis D.P., Bodey G.P., Hanna H., Hachem R., Boktour M., Girgaway E., et al. Outcome determinants of fusariosis in a tertiary care cancer center: the impact of neutrophil recovery. Leuk Lymphoma 2004, 45:139-141.
3. Nucci M., Marr K.A., Queiroz-Telles F., Martins C.A., Trabasso P., Costa S., et al. Fusarium infection in hematopoietic stem cell transplant recipients. Clin Infect Dis 2004, 38:1237-1242.
4. Torres H.A., Raad, Kontoyiannis D.P. Infections caused by Fusarium species. J Chemother 2003, 15:28-35.
5. Nucci M., Anaissie E.J., Queiroz-Telles F., Martins C.A., Trabasso P., Solza C., et al. Outcome predictors of 84 patients with hematologic malignancies and Fusarium infection. Cancer 2003, 98:315-319.
6. Perfect J.R. Treatment of non-Aspergillus moulds in immunocompromised patients, with amphotericin B lipid complex. Clin Infect Dis 2005, 40(Suppl. 6):S401-S408.
7. Perfect J.R., Marr K.A., Walsh T.J., Greenberg R.N., DuPont B., Torre-Cisneros J., et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 2003, 36:1122-1131.
8. De Pauw B., Walsh T.J., Donnelly J.P., Stevens D.A., Edwards J.E., Calandra T., et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008, 46:1813-1821.
9. Hajjeh R.A., Warnock D.W. Counterpoint: invasive aspergillosis and the environment - rethinking our approach to prevention. Clin Infect Dis 2001, 33:1549-1552.
10. Segal B.H., Herbrecht R., Stevens D.A., Ostrosky-Zeichner L., Sobel J., Viscoli C., et al. Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis 2008, 47:674-683.
11. CLSI Reference method for broth dilution antifungal susceptibility testing of filamentous fungi 2008, Clinical and Laboratory Standards Institute, Wayne, PA, CLSI document M38-A2. Approved Standard-Second Edition.
12. Neofytos D., Horn D., Anaissie E., Steinbach W., Olyaei A., Fishman J., et al. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin Infect Dis 2009, 48:265-273.
13. Raad I., Tarrand J., Hanna H., Albitar M., Janssen E., Boktour M., et al. Epidemiology, molecular mycology, and environmental sources of Fusarium infection in patients with cancer. Infect Control Hosp Epidemiol 2002, 23:532-537.
14. Nucci M., Anaissie E. Fusarium infections in immunocompromised patients. Clin Microbiol Rev 2007, 20:695-704.
15. Marom E.M., Holmes A.M., Bruzzi J.F., Truong M.T., O'Sullivan P.J., Kontoyiannis D.P. Imaging of pulmonary fusariosis in patients with hematologic malignancies. AJR Am J Roentgenol 2008, 190:1605-1609.
16. Greene R.E., Schlamm H.T., Oestmann J.W., Stark P., Durand C., Lortholary O., et al. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis 2007, 44:373-379.
17. Nivoix Y., Velten M., Letscher-Bru V., Moghaddam A., Natarajan-Amé S., Fohrer C., et al. Factors associated with overall and attributable mortality in invasive aspergillosis. Clin Infect Dis 2008, 47:1176-1184.
18. Raad, Hanna H.A., Boktour M., Jiang Y., Torres H.A., Afif C., et al. Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin. Leukemia 2008, 22:496-503.
19. Kontoyiannis D.P., Lionakis M.S., Lewis R.E., Chamilos G., Healy M., Perego C., et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis 2005, 191:1350-1360.
20. Ben-Ami R., Lewis R.E., Raad, Kontoyiannis D.P. Phaeohyphomycosis in a tertiary care cancer center. Clin Infect Dis 2009, 48:1033-1041.
21. Lamaris G.A., Chamilos G., Lewis R.E., Safdar A., Raad, Kontoyiannis D.P. Scedosporium infection in a tertiary care cancer center: a review of 25 cases from 1989-2006. Clin Infect Dis 2006, 43:1580-1584.
22. Sipsas N.V., Lewis R.E., Tarrand J., Hachem R., Rolston K.V., Raad I.I., et al. Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001-2007). Cancer 2009, 45:4745-4752.